Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | ASCEND: acalabrutinib in R/R CLL

Paolo Ghia • 17 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Bendamustine Idelalisib Rituximab
ASCEND

Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, Italy, outlines the final results of the Phase III ASCEND study (NCT02970318), evaluating safety and efficacy of acalabrutinib monotherapy in chronic lymphocytic leukemia (CLL) patients in the relapsed/refractory (R/R) setting. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Paolo Ghia

Nemtabrutinib plus venetoclax in R/R CLL: dose escalation and confirmation in the BELLWAVE-010 trial
1:57
Nemtabrutinib plus venetoclax in R/R CLL: dose escalation and confirmation in the BELLWAVE-010 trial
Paolo Ghia • 8 Dec 2025
Treatment options for patients with CLL who have developed resistance to covalent BTK inhibitors
1:15
Treatment options for patients with CLL who have developed resistance to covalent BTK inhibitors
Paolo Ghia • 8 Dec 2025
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
19:55
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
Paolo Ghia • 25 Apr 2025
A study investigating the efficacy of CAR-T therapy in Richter's transformation
1:52
A study investigating the efficacy of CAR-T therapy in Richter's transformation
Paolo Ghia • 27 Sep 2024

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Paolo Ghia • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Paolo Ghia • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Paolo Ghia • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Paolo Ghia • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals